Several studies have shown that some new biomarkers like myelin oligodendrocyte glycoprotein (MOG) antibody, serum IgG targeting myelin basic protein (MBP) and myelin-associated oligodendrocyte basic protein (MOBP) can be used to diagnose and differentiate ADEM from MS at the first attack [67,69,71,72]. This evidence concerns the gene MOBP and myeloid sarcoma.